Not much point selling now!
I’m not expert but 26 weeks seems like an early time point to conclude on efficacy. These poor people hang on for ages and the fall off in function isn’t linear.
What were the researchers expecting? If this is neuroprotective they have all done quite well. If neuro restorative then it is probably a failure. But the extending trial may show a different picture. And it would be terrible to reject a treatment that is good.
I suppose other potential pd drugs are assessed at 26 weeks?
The medics’ interest will be maintained for another 12 months. Investors will turn away for good right now I expect. Big investors will decide.
Ann: Results of LCT Parkinsons trial require further analysis, page-32
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
-0.001(6.25%) |
Mkt cap ! $13.49M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $10.09K | 1.262M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 6170343 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 160758 | 2 |
View Market Depth
| Last trade - 12.05pm 20/08/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |